dapansutrile   Click here for help

GtoPdb Ligand ID: 10056

Synonyms: OLT-1177 | OLT1177
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Dapansutrile (OLT1177) acts as a NLRP3 inflammasome inhibitor. It is a clinical candidate that is being developed by Olatec Therapeutics. Inhibition of the NLRP3 inflammasome reduces maturation of the pro-inflammatory, disease-associated cytokines IL-1β and IL-18 [3]. Immunoprecipitation and FRET analysis indicates that OLT1177 inhibits inflammasome oligomerization by blocking NLRP3-ASC, and NLRP3-caspase-1 interaction, but may also directly target NLRP3 (as assessed by inhibition of recombinant NLRP3 ATPase activity by dapansutrile) [3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

dapansutrile is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 2
Topological polar surface area 66.31
Molecular weight 133.02
XLogP -0.32
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES N#CCCS(=O)(=O)C
Isomeric SMILES N#CCCS(=O)(=O)C
InChI InChI=1S/C4H7NO2S/c1-8(6,7)4-2-3-5/h2,4H2,1H3
InChI Key LQFRYKBDZNPJSW-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Clinical trials using dapansutrile (OLT1177) in acute and chronic inflammatory conditions were initiated, to evaluate both topical and oral efficacy [2,6]. The only active study listed on ClinicalTrials.org in Feb. 2024 was in participants with gouty arthritis. There are also plans to assess dapansutrile to tackle neuroinflammatory pathology in Parkinson's disease [5] based on evidence from preclinical animal models [1].

SARS-CoV-2 and COVID-19: Dapansutrile's anti-inflammatory potential (via oral administration) was planned to be investigated in COVID-19 patients with moderate symptoms, but that clinical trial (NCT04540120) was terminated in response to the successful deployment of anti-SARS-CoV-2 vaccines.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04540120 Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome Phase 2 Interventional Olatec Therapeutics LLC
NCT01768975 Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee Phase 2 Interventional Olatec Therapeutics LLC
NCT02104050 Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain Phase 2 Interventional Olatec Therapeutics LLC